首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1392291

全球氣喘生物製劑市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

Global Asthma Biologics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年11月01日 | 出版商:

Value Market Research | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球氣喘生物製劑市場需求預計將從 2022 年的 72.9 億美元增至 2030 年的近 201.6 億美元，2023-2030 年研究期間CAGR為 13.56%。

氣喘生物製劑是一種用於治療氣喘的藥物，其特徵是發炎和氣道狹窄。與支氣管擴張劑和皮質類固醇等傳統氣喘藥物不同，生物製劑是一類新型藥物，針對參與發炎反應的特定途徑的免疫系統。

市場動態：

氣喘生物製劑市場受到多種因素的推動，包括嚴重氣喘盛行率的不斷上升、生物技術的進步以及對個人化醫療的日益重視。對氣喘病理生理學的了解不斷加深，以及對更有效、更安全的治療方法的渴望，推動了生物製劑的開發和採用。全球醫療保健支出的不斷成長，加上監管部門批准的擴大，促進了市場的成長。隨著患者和醫療保健專業人員意識的增強，人們越來越認知到生物製劑在治療嚴重、不受控制的氣喘方面的益處。市場的動態是由持續的研究、技術進步和對創新解決方案的追求決定的，反映了氣喘治療不斷變化的格局。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球氣喘生物製劑市場的各個細分市場進行了包容性評估。氣喘生物製品產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲氣喘生物製品市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。氣喘生物製劑市場的主要參與者包括安進公司、阿斯特捷利康公司、羅氏公司、葛蘭素史克公司、諾華公司、再生元製藥公司、賽諾菲公司、梯瓦製藥工業有限公司等。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：氣喘生物製劑公司的競爭格局

氣喘生物製劑市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Amgen Inc.

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

GSK plc

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Regeneron Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd.

公司簡介
公司收入
產品
最近的發展

Other

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112800

The global demand for Asthma Biologics Market is presumed to reach the market size of nearly USD 20.16 BN by 2030 from USD 7.29 BN in 2022 with a CAGR of 13.56% under the study period 2023 - 2030.

Asthma biologics are a type of medication used in the treatment of asthma, which is characterized by inflammation and narrowing of the airways. Unlike traditional asthma medications such as bronchodilators and corticosteroids, biologics are a newer class of drugs that target the immune system at specific pathways that are involved in the inflammatory response.

MARKET DYNAMICS:

The asthma biologics market is propelled by several factors, including the escalating prevalence of severe asthma, advancements in biotechnology, and a growing emphasis on personalized medicine. The increased understanding of asthma pathophysiology and a desire for more effective and safer therapies have driven the development and adoption of biologics. The rising global healthcare expenditure, coupled with expanding regulatory approvals, contributes to the market's growth. As awareness among patients and healthcare professionals grows, there is greater recognition of the benefits of biologics in managing severe, uncontrolled asthma. The market's dynamics are shaped by ongoing research, technological progress, and the quest for innovative solutions, reflecting the evolving landscape of asthma treatment.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of asthma biologics. The growth and trends of asthma biologics industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the asthma biologics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Selective Immuno-Suppressants
Interleukin Inhibitors
Others

By Distribution Channel

Retail Pharmacies
E-Commerce
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Asthma Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Asthma Biologics market include Amgen, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., GSK plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Other. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ASTHMA BIOLOGICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ASTHMA BIOLOGICS MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Selective Immuno-suppressants Historic and Forecast Sales by Regions
5.5 Interleukin Inhibitors Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ASTHMA BIOLOGICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by Distribution Channel
6.4 Retail Pharmacies Historic and Forecast Sales by Regions
6.5 E-commerce Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL ASTHMA BIOLOGICS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ASTHMA BIOLOGICS COMPANIES

8.1. Asthma Biologics Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ASTHMA BIOLOGICS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Amgen Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. AstraZeneca
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. F. Hoffmann-La Roche Ltd.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. GSK plc
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Novartis AG
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Regeneron Pharmaceuticals Inc.
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Sanofi
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Teva Pharmaceutical Industries Ltd.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Other
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments